Disclosure Of Non-Current Assets Held For Sale And Discontinued Operations [Text Block]

Innate Pharma - Filing #2811003

Concept 2023-01-01 to
2023-12-31
2022-01-01 to
2022-12-31
Disclosure of non-current assets held for sale and discontinued operations [text block]
Disclosure of analysis of single amount of discontinued operations [text block]
Disclosure of analysis of single amount of discontinued operations [abstract]
Disclosure of analysis of single amount of discontinued operations [line items]
Profit (loss) before tax
7 570 EUR
57 972 EUR
Revenue
61 641 EUR
57 674 EUR
Profit (loss) from discontinued operations
EUR
131,000 EUR
Cash flows from continuing and discontinued operations [abstract]
Cash flows from (used in) operating activities [abstract]
Cash flows from (used in) operating activities
32 558 EUR
19 155 EUR
Cash flows from (used in) investing activities [abstract]
Cash flows from (used in) investing activities
20 631 EUR
1 877 EUR
Cash flows from (used in) financing activities [abstract]
Cash flows from (used in) financing activities
1 966 EUR
1 828 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.